The EIF4G3 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for investigating translational control in non-small cell lung cancer. This product comprises a pool of NCI-H1299 cells harboring targeted disruptions in the EIF4G3 gene, generated via CRISPR/Cas9-mediated gene editing. The polyclonal format captures a range of knockout alleles, offering a robust model to assess the consequences of EIF4G3 loss of function without clonal selection bias. These cells are suitable for studying cap-dependent translation initiation and its role in oncogenic signaling. The knockout effect results in impaired assembly of the eIF4F complex, providing a tool for exploring translation-dependent phenotypes.
The NCI-H1299 host cell line originates from a lymph node metastasis of a lung adenocarcinoma, serving as a widely employed model for non-small cell lung cancer biology. This cell line exhibits characteristic features of lung epithelial carcinoma, including deregulated growth factor signaling and altered apoptotic pathways, making it a valuable system for probing oncogenic mechanisms. NCI-H1299 cells are frequently utilized in studies of PI3K/AKT and MAPK/ERK pathway activation, as well as resistance to targeted therapies. The EIF4G3 knockout context allows dissection of how translation initiation contributes to the transformed phenotype in this lineage.
EIF4G3 encodes a large scaffold protein that bridges the cap-binding protein eIF4E with eIF4A and eIF3, forming the eIF4F complex for cap-dependent translation. This complex recruits the 43S preinitiation complex for ribosome scanning. Upstream, mTOR and ERK kinases phosphorylate 4E-BP1 and eIF4G3, modulating complex assembly. Knockout of EIF4G3 destabilizes eIF4F, selectively suppressing translation of mRNAs with structured 5?? UTRs, such as those encoding growth factors. This loss attenuates PI3K/AKT and RAS-driven proliferation by reducing translation of key oncogenic effectors.
In the NCI-H1299 background, EIF4G3 knockout is expected to compromise the translation of oncogenic mRNAs critical for maintaining the malignant phenotype of non-small cell lung cancer cells. This model enables the investigation of how cap-dependent translation contributes to uncontrolled proliferation and evasion of apoptosis in a lung adenocarcinoma setting. Because NCI-H1299 cells harbor mutations in TP53 and display activated KRAS signaling, the loss of EIF4G3 provides insight into synthetic vulnerabilities that may arise when translational control is disrupted. Researchers can employ this knockout to assess changes in cell growth kinetics, apoptotic responses, and sensitivity to chemotherapeutics or targeted agents that intersect with mTOR and MAPK pathways.
This polyclonal knockout cell product is ideally suited for a spectrum of functional assays, including ribosome profiling to quantify translation changes, Western blotting to monitor eIF4F complex components and signaling markers, and RT-qPCR to assess transcript levels of known EIF4G3 targets. It also supports high-throughput synthetic lethality screens to identify genes whose inhibition synergizes with translation impairment, and drug sensitivity profiling against inhibitors of mTOR, PI3K, or ERK pathways. Additionally, phenotypic assays such as cell migration, invasion, and apoptosis can delineate the role of EIF4G3 in metastatic behavior. For further technical inquiries or custom engineering services, please contact Ascent Research.
